Breaking News Instant updates and real-time market news.

BAC

Bank of America

$30.66

0.11 (0.36%)

, INTC

Intel

$43.41

0.91 (2.14%)

07:36
01/12/18
01/12
07:36
01/12/18
07:36

Unusual call flow in option market yesterday

Notable call activity was cited Thursday in Bank of America (BAC), Intel (INTC), Teva (TEVA), Costco (COST), UPS (UPS), Johnson & Johnson (JNJ), Kinder Morgan (KMI), Las Vegas Sands (LVS), NRG Energy (NRG), and Wendy's (WEN).

BAC

Bank of America

$30.66

0.11 (0.36%)

INTC

Intel

$43.41

0.91 (2.14%)

TEVA

Teva

$21.74

1.7 (8.48%)

COST

Costco

$189.38

3.96 (2.14%)

UPS

UPS

$133.46

3.67 (2.83%)

JNJ

Johnson & Johnson

$144.79

0.82 (0.57%)

KMI

Kinder Morgan

$19.20

0.32 (1.69%)

LVS

Las Vegas Sands

$70.63

0.59 (0.84%)

NRG

NRG Energy

$28.61

0.37 (1.31%)

WEN

Wendy's

$17.24

-0.09 (-0.52%)

  • 17

    Jan

  • 23

    Jan

  • 15

    Feb

  • 16

    Feb

BAC Bank of America
$30.66

0.11 (0.36%)

01/09/18
SOCG
01/09/18
DOWNGRADE
Target $33
SOCG
Hold
Bank of America downgraded to Hold from Buy at Societe Generale
Societe Generale analyst Andrew Lim downgraded Bank of America to Hold saying the stock is now fairly priced following the recent rally. The analyst raised his price target for the shares to $33 from $32.
10/16/17
BMOC
10/16/17
NO CHANGE
Target $29
BMOC
Market Perform
Bank of America price target raised to $29 from $27 at BMO Capital
BMO Capital analyst James Fotheringham raised his price target on Bank of America following Q3 earnings to reflect higher than expected net interest margins. Fotheringham notes that among the top four banks, Bank of America is the only one offering positive return potential. The analyst also sees positive broader trends and an opportunity to buy credit-sensitive stocks, as "investors remain bullish on rates but bearish on credit". Fotheringham maintains a Market Perform rating on Bank of America.
12/20/17
WELS
12/20/17
NO CHANGE
Target $35
WELS
Outperform
Bank of America price target raised to $35 from $30 at Wells Fargo
Wells Fargo analyst Mike Mayo raised his price target for Bank of America to $35 from $30 to reflect more potential upside from a portion of higher interest rates, lower taxes, and lower cost of capital due to greater resiliency. The analyst reiterates an Outperform rating on the shares.
08/09/17
WELS
08/09/17
INITIATION
WELS
Outperform
Bank of America resumed with an Outperform at Wells Fargo
Wells Fargo analyst Mike Mayo resumed coverage of Bank of America with an Outperform rating and $30 price target.
INTC Intel
$43.41

0.91 (2.14%)

01/05/18
RHCO
01/05/18
NO CHANGE
Target $43
RHCO
Hold
Intel security vulnerability 'brings the stock to earth', says SunTrust
SunTrust analyst William Stein keeps his Hold rating and $43 price target on Intel (INTC) in the wake of its security flaw disclosure. Stein says the rally in the stock since Q3 report was overdone to the upside, adding that the latest downside reaction, though likely overdone, puts the price around appropriate valuation. The analyst contends that consumers may favor alternative providers for parallel workload acceleration over Intel's solutions, adding that its latest issues strengthen his view on NVIDIA (NVDA).
01/05/18
ARGS
01/05/18
NO CHANGE
Target $50
ARGS
Buy
Intel chip performance issues are minor, says Argus
Argus analyst Jim Kelleher keeps his Buy rating and $50 price target on Intel amid stock price pressure from concerns about hardware vulnerabilities in the company's computer processors. Kelleher says that while Intel's reputation may have taken a hit, he sees no reason to deem the issue material for business, noting that a 2%-3% degradation in performance from installation of a software patch should be invisible to most users. The analyst says Intel stock is attractive at current levels even above the high end of its multiyear range.
01/11/18
NEED
01/11/18
NO CHANGE
Target $76
NEED
Buy
Report caused confusion about Micron, Intel 3D NAND pact, says Needham
Following a media report about Micron (MU) and Intel (INTC) parting ways in the co-development of 3D NAND, Needham analyst Rajvindra Gill spoke with Micron CFO Ernie Maddok at CES. Gill believes the report caused some confusion and he said the only change to their NAND agreement is that the two companies will go their separate ways in the development of fourth generation 3D NAND IP. Micron management's view is this is a "no-brainer," as being able to develop unique IP should allow the company to broaden its addressable market by 2021, said Gill, who added that the current pact is very strict on the usage of the co-developed IP and he sees no risk of Intel licensing to Chinese manufacturers. The analyst, who also believes current NAND pricing decline concerns are overblown, keeps a Buy rating and $76 price target on Micron shares.
01/04/18
FBCO
01/04/18
NO CHANGE
Target $42
FBCO
Neutral
Intel selloff an 'overreaction,' says Credit Suisse
Credit Suisse analyst John Pitzer says that while he does not find current valuation particularly compelling, the selloff related to speculation of security issues appears to have been an "overreaction." The analyst reiterates a Neutral rating and $42 price target on the shares.
TEVA Teva
$21.74

1.7 (8.48%)

01/09/18
MZHO
01/09/18
UPGRADE
MZHO
Buy
Teva upgraded to Buy from Neutral at Mizuho
01/09/18
01/09/18
UPGRADE
Target $23

Buy
Teva upgraded to Buy at Mizuho
As previously reported, Mizuho analyst Irina Koffler upgraded Teva to Buy from Neutral after updating her model for heavier cost cutting, 2017 asset divestitures and slower generic deterioration. The analyst also raised her price target on the shares to $23 from $16.
01/09/18
BMOC
01/09/18
NO CHANGE
Target $26
BMOC
Outperform
Alder Biopharmaceuticals price target raised to $26 from $22 at BMO Capital
BMO Capital analyst Matthew Luchini raised his price target on Alder Biopharmaceuticals (ALDR) to $26 after the release of PROMISE-2 Phase III data in chronic migraine and announcement of settlement with Teva (TEVA) which allows Alder to operate internationally. Luchini says the Phase III update for PROMISE-2 indicates a "competitive profile with potential advantage in chronic setting" for the eptinezumab drug with superior response rates relative to competition. The analyst is keeping his Outperform rating on Alder Biopharmaceuticals.
01/11/18
GSCO
01/11/18
NO CHANGE
Target $25
GSCO
Buy
Teva price target raised to $25 from $20 at Goldman Sachs
Goldman analyst Jami Rubin raised Buy rated Teva's price target to $25 from $20 following the recent investor presentation and management meetings. The analyst believes investor concerns regarding debt issue/downgrade risk combine with the impact from topline portfolio optimization are overstated. Rubin believes there could actually be upside to Copaxone estimates and further FTF opportunities and has increased confidence in the company's deleveraging path.
COST Costco
$189.38

3.96 (2.14%)

01/02/18
BARD
01/02/18
NO CHANGE
Target $215
BARD
Outperform
Costco traffic tends should remain best-in-class, says Baird
Baird analyst Peter Benedict said Costco's traffic trends should remain the best-in-class while its core comps should continue to stand out. Also, a favorable calendar shift is an added boost and gas and foreign exchange remain tailwinds. Benedict said Costco remains a compelling staple idea and reiterated his Outperform rating and $215 price target on the shares.
01/12/18
OPCO
01/12/18
NO CHANGE
Target $210
OPCO
Outperform
Costco well positioned to benefit from Sam's closures, says Oppenheimer
After examining Walmart's (WMT) plans to shutter more than 60 of its Sam's Club units, Oppenheimer analyst Brian Nagel believes Costco (COST) is well situated to potentially capitalize upon both "freed up" sales and "dislocated" Sam's members. He views the Sam's closings as an "incremental positive" to his investment thesis and keeps an Outperform rating on Costco with a $210 price target.
01/04/18
MONN
01/04/18
NO CHANGE
MONN
Ulta rises after Monness Crespi calls company a better Amazon 'target'
Pre-market strength in shares of Ulta Beauty (ULTA) is being attributed to a suggestion made by an analyst at Monness Crespi that the company could be a better M&A fit for Amazon (AMZN) than Target (TGT). AMAZON ALTERNATIVES: In a note to investors this morning, Monness, Crespi, Hardt analyst James Cakmak noted the speculation that has swirled since Amazon's deal to buy Whole Foods about what categories and kinds of companies the e-commerce giant might acquire. He also noted that Target (TGT) most recently "has been floated as a prospect," but he doesn't see how such a deal would "change the game" in terms of pricing and selection for Amazon. Beauty is a category important for Amazon, and Ulta Beauty could be an M&A fit, Cakmak said. Lyft would also makes sense, as would a purchase of Costco (COST), even though that hypothetical deal "is highly unlikely," Cakmak also told investors. WHAT'S NOTABLE: Cakmak's note appears to be in response to Loup Venture's Gene Munster having said yesterday that Amazon may be eyeing Target as its next major retail acquisition. PRICE ACTION: In pre-market trading, Ulta is up $4.78, or 2%, to $249.90 per share.
01/08/18
OPCO
01/08/18
NO CHANGE
Target $210
OPCO
Outperform
Costco price target raised to $210 from $180 at Oppenheimer
Oppenheimer analyst Brian Nagel raised his price target for Costco to $210 from $180 as he continues to view it as particularly well-positioned among larger-cap retailers. The analyst believes new tax legislation will afford Costco more opportunity to invest strategically to further solidify its competitive standing in a shifting retail landscape. Further, Nagel expects continued solidifying fundamentals to further ease market concerns and support the premium Costco valuation. He reiterates an Outperform rating on the shares.
UPS UPS
$133.46

3.67 (2.83%)

01/02/18
FBCO
01/02/18
NO CHANGE
FBCO
Parcel shipping rates should rise over long-term, says Credit Suisse
Credit Suisse analyst Allison Landry notes that on the back of President Trump's tweet late last week, questions have resurfaced as to whether the USPS has been subsidizing Amazon's (AMZN) logistics costs by charging below market rates in the competitive parcel market, and using its monopoly power in First Class mail to cross-subsidize parcel delivery costs. The analyst believes this is yet another data point that supports her thesis that parcel shipping rates will rise over the long-term as she sees the potential for Postal Reform to be addressed by Congress in 2018. Landry thinks it is only a matter of time before the USPS is forced to raise rates in its package business, which would be a clear positive for FedEx (FDX) and UPS (UPS).
12/11/17
MSCO
12/11/17
NO CHANGE
MSCO
Underweight
Negative sentiment shift a concerning sign for UPS, says Morgan Stanley
Following recent media reports of service issues at UPS (UPS), Morgan Stanley analyst Ravi Shanker analyzed Google searches and online sentiment regarding the company and found a sharper than usual increase in negative sentiment regarding the brand, while finding similar to normal seasonal patterns for competitor FedEx (FDX). The analyst does not think higher volumes, which are the likely cause of the service issues, are necessarily a net positive, as the cost associated with moving the higher volumes could be a significant headwind and the issues could exacerbate any potential share loss headwinds also. Shanker, who concludes that it "could be a challenging quarter" for UPS, keeps an Underweight rating on the stock.
01/08/18
DBAB
01/08/18
NO CHANGE
Target $145
DBAB
Buy
Deutsche names UPS a Top Pick, ups price target to $145
Deutsche Bank analyst Amit Mehrotra raised his price target for UPS (UPS) to $145 and $135 and elevated the shares to Top Pick status in Air Freight & Logistics, along with Knight-Swift (KNX), FedEx (FDX) and XPO Logistics (XPO). The analyst's earnings estimates for UPS have been revised 10% higher to reflect the passage of corporate tax reform. He also estimates that tax reform equates to about $1B of incremental free cash flow per annum. 5% cash tax rate. Mehrotra believes UPS shares are underappreciated and he maintains a Buy rating on the name.
01/04/18
SBSH
01/04/18
NO CHANGE
Target $304
SBSH
Buy
Citi says all Transports win under U.S. tax bill
The Tax Cut and Jobs Act drives a "meaningful step up" in earnings as well as free cash flow for essentially all names in Transportation, Citi analyst Christian Wetherbee tells investors in a research note. He sees U.S. Rails as likely the biggest winners from tax reform. In most cases companies will use the cash "windfall" for buybacks, Wetherbee tells investors in a research note. He believes, however, that a compelling case can be made for U.S. Rails to increase dividends by 15%-20%. The free cash flow windfall could save UPS's (UPS) buyback program, which looked likely to decline in 2018 under the weight of accelerating capex, the analyst adds. Wetherbee upgraded C.H. Robinson Worldwide (CHRW) to Buy and downgraded Schneider National (SNCR) to Neutral. He also raised his price target for Buy-rated FedEx (FDX) to $304 from $280, Buy-rated CSX (CSX) to $64 from $58 and for Buy-rated UPS to $143 from $128.
JNJ Johnson & Johnson
$144.79

0.82 (0.57%)

01/02/18
JPMS
01/02/18
DOWNGRADE
Target $150
JPMS
Neutral
Johnson & Johnson downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Michael Weinstein downgraded Johnson & Johnson (JNJ) to Neutral with an unchanged price target of $150. The stock closed Friday down 81c to $139.72. The analyst sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. He remains "fundamentally bullish" on the company, however. Weinstein this morning upgraded both Abbott Laboratories (ABT) and Baxter International (BAX) to Overweight.
01/02/18
01/02/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) downgraded to Neutral from Overweight at JPMorgan with analyst Michael Weinstein saying he sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. 2. PG&E (PCG) downgraded to Sell from Neutral at Guggenheim and to Neutral from Buy at Goldman Sachs. Goldman analyst Michael Lapides saying resolution of claims from the California wildfires, if inverse condemnation is applied, could take years and "cash flow/balance sheet impacts could prove significant still." 3. Allstate (ALL) downgraded to Underperform from Market Perform at Keefe Bruyette with analyst Meyer Shields saying the company's margin expansion story has played out. 4. Cabot Oil & Gas (COG) downgraded two notches to Underperform from Outperform at Raymond James with analyst John Freeman citing valuation after "considerable" 2017 share outperformance. 5. Windstream (WIN) downgraded to Underweight from Neutral at JPMorgan with analyst Philip Cusick saying he sees fundamental business challenges continuing in both the near and long term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/04/18
RBCM
01/04/18
NO CHANGE
Target $54
RBCM
Outperform
Pacira price target raised to $54 from $50 at RBC Capital
RBC Capital analyst Randall Stanicky raised his price target on Pacira (PCRX) to $54 and kept his Outperform rating. Stanicky says his focus is on the company's expected pre-announcement for Q4 this week and his upcoming discussion with CEO Dave Stack on Monday regarding changes from CMS around unbundling of payments that could represent a game changing opportunity for the company's EXPAREL. The analyst notes that traction is building around Pacira's relationship with Johnson & Johnson (JNJ) on the ortho selling side, which marks about half of its revenue.
12/13/17
LEER
12/13/17
NO CHANGE
Target $120
LEER
Outperform
Myeloma data good for Johnson & Johnson, neutral to Celgene, says Leerink
Leerink analyst Geoffrey Porges notes that during the late breaking abstract session at ASH a "very impressive" dataset was presented highlighting that the addition of Darzalex to standard of care combination VMP improves survival outcomes in newly diagnosed myeloma patients who are ineligible for transplant. The analyst points out that it is no secret that Johnson & Johnson (JNJ) would like to move daratumumab into frontline therapy in myeloma, and this trial is its best near-term opportunity. Porges believes that the trial success is positive for Johnson & Johnson/daratumumab and neutral for Celgene (CELG)/Revlimid. He reiterates an Outperform rating and $120 price target on Celgene's shares.
KMI Kinder Morgan
$19.20

0.32 (1.69%)

01/04/18
FBCO
01/04/18
INITIATION
Target $23
FBCO
Outperform
Kinder Morgan initiated with an Outperform at Credit Suisse
Credit Suisse analyst Kristina Kazarlan initiated Kinder Morgan with an Outperform rating and a price target of $23. The analyst says the valuation suggests the MLP may not need a direct catalyst, adding that "a quiet but well-executed 2018" justifies the rating.
01/09/18
BOFA
01/09/18
INITIATION
Target $20
BOFA
Neutral
Kinder Morgan reinstated with a Neutral at BofA/Merrill
BofA/Merrill analyst Dennis Coleman reinstated coverage on Kinder Morgan with a Neutral and $20 price target.
01/11/18
WELS
01/11/18
DOWNGRADE
Target $21
WELS
Market Perform
Kinder Morgan downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Michael Blum downgraded Kinder Morgan to Market Perform and cut his price target for the shares to $21 from $24. The combination of "still persistently high" leverage and the headline risk associated with the TransMountain pipeline expansion project could weigh on shares, Blum tells investors in a research note.
01/11/18
01/11/18
UPGRADE

Overweight
TransCanada upgraded on defensive positioning, valuation at Morgan Stanley
As previously reported, Morgan Stanley analyst Tom Abrams upgraded TransCanada (TRP) to Overweight from Equal Weight as he believes Midstream valuations are now more defensibly attractive and he prefers the companies in the space with some defensive characteristics. He also has Overweight ratings on Williams (WMB), Williams Partners (WPZ), Enterprise Products (EPD) and Kinder Morgan (KMI).
LVS Las Vegas Sands
$70.63

0.59 (0.84%)

11/22/17
UBSW
11/22/17
NO CHANGE
UBSW
UBS raises Macau estimates after positive survey
UBS analyst Robin Farley said the firm's proprietary Macau survey suggests better than expected junket trends and a further increase in VIP capacity, with higher end mass gaming revenue outpacing low end mass. The analyst raised estimates on the Macau gaming companies, noting that she prefers Wynn (WYNN) and Melco Resorts & Entertainment (MLCO) shares.
01/08/18
STFL
01/08/18
NO CHANGE
STFL
Norwegian Cruise Line added to Select List, SeaWorld called a top pick at Stifel
Stifel analyst Steven Wieczynski named SeaWorld (SEAS) as his top overall pick in Gaming and Leisure for 2018, citing signs of improvement in its core operating fundamentals and a "compelling" relative valuation. He raised his price target on SeaWorld shares to $17 from $15. He also called Norwegian Cruise Line (NCLH) and Las Vegas Sands (LVS) top ideas for 2018, raising his price target on Las Vegas Sands to $476 from $72 and adding Norwegian to the firm's Select List.
01/04/18
DBAB
01/04/18
NO CHANGE
Target $183
DBAB
Buy
Deutsches says Wynn Resorts 'the one to buy' in Gaming
Deutsche Bank analyst Carlo Santarelli raised his price target for Wynn Resorts (WYNN) to $183 from $170 and says the stock is the "one to buy" in Gaming. The analyst believes "late cycle dynamics could become clearer" in 2018 regarding Las Vegas trends and he prefers to play the "hot hand." He thinks Wynn can outperform and keeps a Buy rating on the shares. Santarelli also raised his price target for Hold-rated MGM Resorts (MGM) to $38 from $37 and for Hold-rated Las Vegas Sands (LVS) to $65 from $63.
12/07/17
LEHM
12/07/17
NO CHANGE
Target $75
LEHM
Overweight
Las Vegas Sands price target raised to $75 from $69 at Barclays
Barclays analyst Felicia Hendrix raised her price target for Las Vegas Sands to $75 after the company presented at his firm's conference. The company remains optimistic that mass gaming will drive Macau's growth for the long term, Hendrix tells investors in a research note. To reflect faster than expected market gross gaming revenue growth, the analyst raised her Q4 Macau EBITDA estimate. Hendrix keeps an Overweight rating on the shares.
NRG NRG Energy
$28.61

0.37 (1.31%)

05/24/17
FBCO
05/24/17
NO CHANGE
FBCO
Outperform
Exelon a net winner despite 'disappointing' 2020/21 auction, says Credit Suisse
Following PJM Interconnection's annual capacity auction, Credit Suisse analyst Michael Weinstein called Exelon a net winner despite "disappointing" RPM results for the 2020/21 capacity auction. The results for the EMAAC area should help drive a net positive result for Exelon assuming the same amount of capacity cleared year-over-year, he indicated. PSEG (PEG) and Calpine (CPN)are also "net beneficiaries," while Dynegy (DYN), NRG Energy (NRG) and FirstEnergy (FE) will "bear the brunt of a poor RTO showing," Weinstein tells investors.
06/01/17
UBSW
06/01/17
UPGRADE
Target $20
UBSW
Buy
NRG Energy upgraded to Buy from Neutral at UBS
UBS analyst Julien Dumoulin-Smith upgraded NRG Energy to Buy and raised his price target for the shares to $20 from $19. The proposed GenOn settlement is a positive and, along with the latest PJM auction, adds "clarity to the story," Dumoulin-Smith tell investors in a research note. He also views the NRG's cost cutting initiative as the major near-term catalyst for the shares.
07/13/17
LEHM
07/13/17
NO CHANGE
Target $27
LEHM
Overweight
NRG Energy price target raised to $27 from $20 at Barclays
Barclays analyst Daniel Ford raised his price target for NRG Energy to $27 saying the company's transformation plan is "significantly accretive." NRG's plan to sell between a 50%-100% stake in NRG Yield and Renewables, plus 6GWs of conventional generation can achieve management's projected $2.0B-$4.5B in cash proceeds and reduction of $8.7B in debt, Ford tells investors in a research note. His upside case has $11 per share of valuation accretion to $38 per share. The analyst reiterates an Overweight rating on the shares.
08/16/17
DBAB
08/16/17
NO CHANGE
Target $38
DBAB
Buy
NRG Energy shares have 50% more upside, says Deutsche Bank
Deutsche Bank analyst Abe Azar raised his price target for NRG Energy shares to $38 from $27 to reflect the company's planned transformation. Even with the rally year-to-date, NRG is still trading at an "unwarranted significant discount to peers," Azar tells investors in a research note titled "Baby, we were born to run." The analyst believes the stock has an additional 50% upside and reiterates a Buy rating on the name. Asset sales throughout the year and an investor day early next year set up a "favorable catalyst calendar and should lead to the stock to re-rate higher," Azar writes.
WEN Wendy's
$17.24

-0.09 (-0.52%)

12/20/17
12/20/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. United Continental (UAL) upgraded to Buy from Neutral at Buckingham with the firm citing the active steps the company is taking to address revenue weakness, its commercial initiatives, a favorable macro backdrop that is driving booking strength, and the longer term cash implications of tax reform. 2. Wendy's (WEN) upgraded to Outperform from Neutral at Wedbush with analyst Nick Setyan citing "solid" same-store sales growth and visibility into free cash flow generation. 3. Biogen (BIIB) upgraded to Outperform from Neutral at Credit Suisse with analyst Alethia Young saying a "significant turnaround" is underway for Biogen's business. 4. Steel Dynamics (STLD) was upgraded to Buy from Neutral at Longbow while, U.S. Steel (X), AK Steel (AKS), and Nucor (NUE) were upgraded to Buy from Neutral. 5. Zimmer Biomet (ZBH) upgraded to Neutral from Sell at Goldman Sachs with analyst Isaac Ro saying he sees Bryan Hanson's CEO appointment as a positive step forward in the turnaround process, although he noted that the company's fundamentals are still challenged and the turnaround will take time. Shares were also upgraded to Outperform from Market Perform at Wells Fargo. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/12/18
LBOW
01/12/18
DOWNGRADE
LBOW
Neutral
Wendy's downgraded to Neutral from Buy at Longbow
12/20/17
12/20/17
UPGRADE
Target $20

Outperform
Wendy's upgraded to Outperform at Wedbush
As previously reported, Wedbush analyst Nick Setyan upgraded Wendy's to Outperform from Neutral on "solid" same-store sales growth and visibility into free cash flow generation. The analyst also raised his price target on the shares to $20 from $16.
01/03/18
RHCO
01/03/18
NO CHANGE
Target $22
RHCO
Buy
Wendy's price target raised to $22 from $17 at SunTrust
SunTrust analyst Jake Bartlett raised his price target on Wendy's (WEN) to $22 as part of his "Buy the Tax News" research note on Restaurants. Bartlett says Wendy's multiple will expand to reflect investors' appreciation of the company's accelerating free cash flows and unit growth as it benefits from lower corporate tax rates. The analyst also expects the personal tax relief to support same store sales at Wendy's despite the greater focus on the value offered at McDonald's (MCD).

TODAY'S FREE FLY STORIES

FCX

Freeport McMoRan

$19.96

0.56 (2.89%)

21:10
01/21/18
01/21
21:10
01/21/18
21:10
Downgrade
Freeport McMoRan rating change at CIBC »

Freeport McMoRan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

DCM

NTT DoCoMo

$24.74

0.08 (0.32%)

21:09
01/21/18
01/21
21:09
01/21/18
21:09
Downgrade
NTT DoCoMo rating change at HSBC »

NTT DoCoMo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$53.01

0.65 (1.24%)

, PETS

PetMed Express

$53.24

2.67 (5.28%)

20:25
01/21/18
01/21
20:25
01/21/18
20:25
Earnings
Notable companies reporting before Monday's open »

Notable companies…

HAL

Halliburton

$53.01

0.65 (1.24%)

PETS

PetMed Express

$53.24

2.67 (5.28%)

OPB

Opus Bank

$28.70

0.05 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

FB

Facebook

$181.29

1.49 (0.83%)

, NYT

New York Times

$21.90

1.7 (8.42%)

20:00
01/21/18
01/21
20:00
01/21/18
20:00
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

FB

Facebook

$181.29

1.49 (0.83%)

NYT

New York Times

$21.90

1.7 (8.42%)

NWSA

News Corp.

$17.22

0.21 (1.23%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

SNE

Sony

$49.89

0.72 (1.46%)

BA

Boeing

$337.73

-2.43 (-0.71%)

WMT

Walmart

$104.59

0.29 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 07

    Feb

  • 20

    Feb

  • 21

    Feb

  • 28

    Feb

  • 18

    Mar

XRX

Xerox

$31.80

0.43 (1.37%)

19:18
01/21/18
01/21
19:18
01/21/18
19:18
Periodicals
Icahn, Deason pushing for Xerox to explored sale, WSJ reports »

Carl Icahn and Darwin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

1.49 (0.83%)

18:22
01/21/18
01/21
18:22
01/21/18
18:22
Periodicals
Facebook to open three new digital training hubs in Europe, Reuters says »

Facebook said it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 28

    Feb

TWX

Time Warner

$93.36

0.39 (0.42%)

, CMCSA

Comcast

$42.50

0.65 (1.55%)

17:56
01/21/18
01/21
17:56
01/21/18
17:56
Hot Stocks
Box Office Battle: 'Jumanji' wins weekend with $20M »

Once again, Sony's…

TWX

Time Warner

$93.36

0.39 (0.42%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

SNE

Sony

$49.89

0.72 (1.46%)

FOX

21st Century Fox

$36.26

0.53 (1.48%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

LGF.A

Lionsgate

$35.42

0.92 (2.67%)

DIS

Disney

$110.59

0.17 (0.15%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

CTIC

CTI BioPharma

16:11
01/21/18
01/21
16:11
01/21/18
16:11
Conference/Events
CTI BioPharma to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

ZSAN

Zosano Pharma

$0.45

-0.0387 (-7.92%)

16:00
01/21/18
01/21
16:00
01/21/18
16:00
Conference/Events
Zosano Pharma to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SANM

Sanmina

$35.45

0.5 (1.43%)

15:39
01/21/18
01/21
15:39
01/21/18
15:39
Conference/Events
Sanmina to hold a conference call »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

12:05
01/21/18
01/21
12:05
01/21/18
12:05
Periodicals
Amazon automated grocery store opens Monday, Reuters says »

Amazon will open its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 18

    Mar

TWTR

Twitter

$23.66

-0.38 (-1.58%)

09:07
01/21/18
01/21
09:07
01/21/18
09:07
Periodicals
Twitter COO in discussions to become SoFi CEO, WSJ reports »

Twitter's COO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

CLF

Cleveland-Cliffs

$8.49

0.08 (0.95%)

09:02
01/21/18
01/21
09:02
01/21/18
09:02
Hot Stocks
Cleveland-Cliffs addresses ''inaccurate media reports' on Nashwauk property »

Cleveland-Cliffs said it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

15:26
01/20/18
01/20
15:26
01/20/18
15:26
Hot Stocks
Opdivo, Yervoy combo demonstrates activity in patients with dMMR, MSI-H mCRC »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 05

    Feb

  • 08

    Feb

  • 05

    Mar

  • 08

    Mar

EXEL

Exelixis

$28.00

0.14 (0.50%)

, RHHBY

Roche

$30.69

0.18 (0.59%)

15:22
01/20/18
01/20
15:22
01/20/18
15:22
Hot Stocks
Exelixis presents updated results from Phase 1b clinical trial in CRC »

Exelixis (EXEL) announced…

EXEL

Exelixis

$28.00

0.14 (0.50%)

RHHBY

Roche

$30.69

0.18 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 01

    Feb

  • 08

    Feb

  • 15

    Feb

  • 23

    Feb

ARRY

Array BioPharma

$13.14

0.26 (2.02%)

15:17
01/20/18
01/20
15:17
01/20/18
15:17
Hot Stocks
Array BioPharma updates results from BEACON Phase 3 trial »

Array BioPharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

  • 30

    Jun

SO

Southern Company

$44.44

-0.46 (-1.02%)

15:13
01/20/18
01/20
15:13
01/20/18
15:13
Hot Stocks
Southern Company accelerates restoration efforts in Puerto Rico »

Southern Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.43

0.19 (0.65%)

15:10
01/20/18
01/20
15:10
01/20/18
15:10
Hot Stocks
Teck Resources announces Elkview incident »

Teck Resources announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

TWTR

Twitter

$23.66

-0.38 (-1.58%)

14:03
01/20/18
01/20
14:03
01/20/18
14:03
Hot Stocks
Twitter begins notifying users exposed to Russian propaganda during elections »

Twitter, which is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

, SPX

S&P 500

13:58
01/20/18
01/20
13:58
01/20/18
13:58
Periodicals
Government shuts down on anniversary of Trump presidency, Reuters reports »

President's Trump…

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

1.49 (0.83%)

, NYT

New York Times

$21.90

1.7 (8.42%)

13:48
01/20/18
01/20
13:48
01/20/18
13:48
Periodicals
NY Times stock jumps after Facebook's announcement, Recode reports »

Facebook (FB) CEO Mark…

FB

Facebook

$181.29

1.49 (0.83%)

NYT

New York Times

$21.90

1.7 (8.42%)

NWSA

News Corp.

$17.22

0.21 (1.23%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 07

    Feb

  • 28

    Feb

WMT

Walmart

$104.59

0.29 (0.28%)

13:36
01/20/18
01/20
13:36
01/20/18
13:36
Periodicals
Still time to shop Walmart shares as company makes changes, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, NFLX

Netflix

$220.46

0.13 (0.06%)

08:59
01/20/18
01/20
08:59
01/20/18
08:59
Periodicals
Netflix among likely candidates for an Apple purchase, Barron's says »

Especially for tech…

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 01

    Feb

BA

Boeing

$337.73

-2.43 (-0.71%)

08:50
01/20/18
01/20
08:50
01/20/18
08:50
Periodicals
Boeing not a sell just yet, Barron's says »

Boeing stock has come…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, EADSY

Airbus

$28.43

0.755 (2.73%)

08:24
01/20/18
01/20
08:24
01/20/18
08:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$178.46

-0.8 (-0.45%)

EADSY

Airbus

$28.43

0.755 (2.73%)

BA

Boeing

$337.73

-2.43 (-0.71%)

VZ

Verizon

$51.91

0.36 (0.70%)

NYT

New York Times

$21.90

1.7 (8.42%)

TWX

Time Warner

$93.36

0.39 (0.42%)

DIS

Disney

$110.59

0.17 (0.15%)

TIME

Time Inc.

$18.55

0.05 (0.27%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

BAC

Bank of America

$31.72

0.24 (0.76%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BK

BNY Mellon

$56.61

1.26 (2.28%)

WLKP

Westlake Chemical Partners

$24.45

-0.1 (-0.41%)

MON

Monsanto

$120.66

1.8 (1.51%)

DLTR

Dollar Tree

$114.73

1.83 (1.62%)

CE

Celanese

$112.96

1.93 (1.74%)

LYB

LyondellBasell

$119.92

3.03 (2.59%)

TSE

Trinseo

$79.45

2.2 (2.85%)

EYE

National Vision

$43.13

1.12 (2.67%)

ETFC

E-Trade

$54.28

0.63 (1.17%)

LPLA

LPL Financial

$59.03

0.53 (0.91%)

AMTD

TD Ameritrade

$55.17

0.21 (0.38%)

SCHW

Charles Schwab

$55.48

0.15 (0.27%)

ADS

Alliance Data

$261.82

5.88 (2.30%)

FISV

Fiserv

$138.11

0.17 (0.12%)

FLT

FleetCor

$206.65

3.4 (1.67%)

HAWK

Blackhawk

$45.25

0.1 (0.22%)

MTZ

MasTec

$53.30

1.25 (2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 25

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 02

    Feb

  • 06

    Feb

  • 07

    Feb

  • 15

    Feb

  • 16

    Feb

  • 21

    Feb

  • 08

    Mar

  • 18

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.